NeuroBo Pharmaceuticals, Inc. Quarterly Costs and Expenses in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
NeuroBo Pharmaceuticals, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2015 to Q2 2024.
  • NeuroBo Pharmaceuticals, Inc. Costs and Expenses for the quarter ending June 30, 2024 was $10.1M, a 165% increase year-over-year.
  • NeuroBo Pharmaceuticals, Inc. Costs and Expenses for the twelve months ending June 30, 2024 was $26.5M, a 33.6% increase year-over-year.
  • NeuroBo Pharmaceuticals, Inc. annual Costs and Expenses for 2023 was $15.9M, a 19.1% decline from 2022.
  • NeuroBo Pharmaceuticals, Inc. annual Costs and Expenses for 2022 was $19.6M, a 28.3% increase from 2021.
  • NeuroBo Pharmaceuticals, Inc. annual Costs and Expenses for 2021 was $15.3M, a 48.5% decline from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $26.5M $10.1M +$6.28M +165% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $20.2M $6.88M +$4.36M +173% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $15.9M $5.67M -$4.76M -45.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 $20.6M $3.89M +$789K +25.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $19.9M $3.81M +$587K +18.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $19.3M $2.52M -$355K -12.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $19.6M $10.4M +$5.85M +128% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $13.8M $3.1M -$360K -10.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $14.1M $3.22M -$707K -18% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $14.8M $2.88M -$455K -13.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $15.3M $4.58M -$14.9M -76.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 $30.2M $3.46M +$404K +13.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $29.8M $3.93M +$1.53M +64.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $28.3M $3.33M -$1.42M -29.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 $29.7M $19.5M +$7.32M +60.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $22.4M $3.06M -$585K -16% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $23M $2.39M +$505K +26.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $22.5M $4.75M +$2.3M +93.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $20.2M $12.2M +$8.89M +269% Oct 1, 2019 Dec 31, 2019 10-K 2021-04-15
Q3 2019 $11.3M $3.65M -$2.26M -38.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 $13.5M $1.89M -$4.65M -71.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 $18.2M $2.45M -$4.61M -65.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-20
Q4 2018 $22.8M $3.3M -$3.27M -49.7% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-18
Q3 2018 $26.1M $5.91M -$2.63M -30.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $28.7M $6.53M -$3.98M -37.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $32.7M $7.06M -$439K -5.85% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $33.1M $6.57M -$661K -9.15% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 $33.8M $8.54M +$5.14M +151% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-18
Q2 2017 $28.6M $10.5M +$8.68M +471% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-18
Q1 2017 $20M $7.5M +$5.28M +237% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-18
Q4 2016 $14.7M $7.23M +$4.72M +188% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-20
Q3 2016 $9.98M $3.4M +$1.04M +43.8% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-20
Q2 2016 $8.94M $1.84M +$230K +14.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-20
Q1 2016 $8.71M $2.23M +$637K +40.1% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-20
Q4 2015 $8.08M $2.51M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-21
Q3 2015 $2.37M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-21
Q2 2015 $1.61M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-21
Q1 2015 $1.59M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.